KDR and cancer: Strong inhibitory effect on VEGFR-2(IC50 = 2.43 nM) may play a key role in the more prominent anti-cancer activity noted in apatinib compared to other VEGFR TKIs, but differences due to patient selection could not be ignored, thus further prospective comparative study may be required.